Synergetics Soars on FDA Clearance

Synergetics

is trading higher on the session followings the FDA clearance yesterday. The company announced its VersaVIT Vitrectomy System for the retinal surgery market as approved by the FDA. David M. Hable, President and CEO said "The entry of VersaVIT into the global vitrectomy market is a major milestone in Synergetics' strategy to enter into higher growth areas of retinal surgery. We believe that VersaVIT is a 'game changer' given its functionality, portability and competitive pricing relative to traditional vitrectomy systems." The Company is awaiting CE mark approval, which has been submitted and is currently under review. Synergetics is currently trading at $4.97, a gain of $1.10 or 28.42%.